Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 11/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2316492 | 0.89 | CASP1 (0.52) | CASP1MAPTTP53RXFP1ELANE | |
| SCHEMBL2316482 | 0.89 | CASP1 (0.52) | CASP1MAPTTP53RXFP1ELANE | |
| SCHEMBL1329937 | 0.88 | ELANE (0.52) | CASP1MAPTTP53RXFP1ELANE | |
| SCHEMBL1329939 | 0.88 | ELANE (0.52) | CASP1MAPTTP53RXFP1ELANE | |
| SCHEMBL2317237 | 0.85 | CASP1 (0.54) | CASP1MAPTTP53RXFP1ELANE | |
| SCHEMBL2317231 | 0.85 | CASP1 (0.54) | CASP1MAPTTP53RXFP1ELANE | |
| SCHEMBL12127800 | 0.84 | MAPT (0.45) | MAPTTP53RXFP1SMN1; SMN2MAPK1 | |
| SCHEMBL2318569 | 0.84 | MAPT (0.45) | MAPTTP53RXFP1SMN1; SMN2MAPK1 | |
| SCHEMBL2317041 | 0.82 | XIAP (0.63) | CASP1MAPTTP53RXFP1SMN1; SMN2 | |
| SCHEMBL2317036 | 0.82 | XIAP (0.63) | CASP1MAPTTP53RXFP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989441-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | claimed |
| US-20090069294-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-03-12 | — | — | US | claimed |
| EP-1902065-A2 | CYCLIC AMIDE DERIVATIVES INHIBITORS OF THE INHIBITOR OF APOPTOSIS PROTEINS, THEIR PREPARATION, AND THEIR USE | Novartis AG (CH) | 2008-03-26 | — | — | EP | claimed |
| WO-2006133147-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-12-14 | — | — | WO | claimed |
| US-20110281845-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-11-17 | — | — | US | disclosed |
| US-7989441-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| US-7989441-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| US-20090069294-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-03-12 | — | — | US | disclosed |
| US-20090069294-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069294-A1 | Organic Compounds | XIAP, BAX, MCL1 | F2 3659/4885PRSS1 3383/4885CASP1 43/4885 |
| US-20110281845-A1 | ORGANIC COMPOUNDS | XIAP, BAX, MCL1 | F2 3657/4885PRSS1 3380/4885CASP1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.